BI-1607

DRUG3 trials

Sponsors

BioInvent International AB

Conditions

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast CancerMelanomaMelanoma BRAF V600E/K MutatedMelanoma MetastaticMelanoma Negative for bRAFMelanoma Negative for nRAS

Phase 1

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

TerminatedNCT05555251

BioInvent International ABHER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer +2

Start: 2022-07-28End: 2024-02-07Updated: 2024-12-16

An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma

Active, not recruitingCTIS2024-512670-10-00

BioInvent International ABUnresectable or Metastatic Melanoma

Start: 2025-02-13Target: 16Updated: 2025-05-22

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Active, not recruitingNCT06784648

BioInvent International ABMelanoma, Melanoma BRAF V600E/K Mutated, Melanoma Metastatic +7

Start: 2024-12-11End: 2025-12-30Target: 35Updated: 2025-11-19

Related Papers

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

2025-12-01

Data from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors

2025-12-01